Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > February 17, 2023
Daily News
February 17, 2023
- Healios Cuts 40 % of Employees Due to MultiStem Development Glitches
February 17, 2023
- Investigators Doubt Mitsubishi’s Trial Data on Muse Cell Therapy; Program Aborted without Notice
February 17, 2023
- JPMA Chief Calls for Prompt Price Cuts for LLPs, Generic Industry Consolidation
February 17, 2023
- Nippon Shinyaku Grabs Japan Rights to Capricor’s DMD Cell Therapy
February 17, 2023
- ViiV Eyes More Uptake for Japan’s 1st Long-Acting HIV Med, Revs Up Development Drive
February 17, 2023
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…